bioRxiv · 10.1101/2020.07.27.223206
ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma
Abstract
Phagocytic immunotherapies such as CD47 blockade have emerged as promising strategies for glioblastoma (GB) therapy, but the blood brain/tumor barriers (BBB/BTB) pose a persistent challenge for mCD47 delivery that can be overcome by focused ultrasound (FUS)-mediated BBB/BTB disruption. We here leverage immuno-PET imaging to determine how timing of [89Zr]-mCD47 injection relative to FUS impacts antibody penetrance into orthotopic murine gliomas. We then design and implement a rational paradigm for combining FUS and mCD47 for glioma therapy. We demonstrate that timing of antibody injection relative to FUS BBB/BTB disruption is a critical determinant of mCD47 access, with post-FUS injection conferring superlative antibody delivery to gliomas. We also show that mCD47 delivery across the BBB/BTB with repeat sessions of FUS can significantly constrain tumor outgrowth and extend survival in glioma-bearing mice. This study generates provocative insights for ongoing pre-clinical and clinical evaluations of FUS-mediated antibody delivery to brain tumors. Moreover, our results confirm that mCD47 delivery with FUS is a promising therapeutic strategy for GB therapy.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Sheybani, N. D., Paul, S., McCauley, K. S., Breza, V., Berr, S. S., Miller, G. W., Neumann, K. D., Price, R. J.. 2020-07-29. ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma. https://doi.org/10.1101/2020.07.27.223206
Cite the original work for its findings. Save a collection to share your selection of sources.